Glycosmedia

Diabetes News Service

  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Genes for type 2 diabetes – are they worth it?

September 14th 2012

A recent publication (1) reported the identification of another ten genes which may predispose to type 2 diabetes (T2DM), bringing the current total to around fifty. However, the impact of these genetic studies from a clinical perspective remains minimal. Forty years after the discovery of the first genes involved in diabetes susceptibility, should we be querying the value of expensive ‘factory floor’ genetics?

A major justification for studies is that new genes will allow for the development of new treatments. Whilst it is true that two of the associated genes (known as PPARG and KCNJ11) are targets for diabetes therapies (glitazones and sulphonylureas respectively), this knowledge has not led to bespoke prescribing; every guideline still recommends initial treatment with metformin. Furthermore, the drug classes had been discovered years before the genes were identified.

A second justification is that identification of genetically at-risk individuals will facilitate the identification of environmental influences which are important in disease development. Whilst this may be of great value in type 1 diabetes, it does not really apply in T2DM where we have a pretty good understanding that diet and weight-gain on the background of a sedentary lifestyle will promote the condition. Add in knowledge of a family history of diabetes and it is difficult to imagine that an individualised genome-wide scan will impart much more information. And that’s before cost is taken into account…

(1). http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2383.html

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsor

Sanofi Diabetes

Gold Sponsors

MSDNovo NordiskBoehringer Ingelheim LillyAstraZenecaNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Share Glycosmedia

Follow us on Twitter

My Tweets

Glycosmedia App

mobileA Glycosmedia iPhone/iPad App is available FREE from the iTunes store.


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


HONcode Standard

HONConduct783211_s2This site complies with the HONcode standard for trustworthy health information: verify here.

Copyright © 2018 Glycosmedia Partnership